Press release
Myositis Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Roche, Pfizer, Zydus Group, Lupin, Bausch Health, Accord Healthcare, Genentech
"Myositis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myositis Market.
The Myositis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Get a Free Sample PDF Report to know more about Myositis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/myositis-pipeline-insight [https://www.delveinsight.com/report-store/myositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key takeaways from the Myositis Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Myositis treatment therapies with a considerable amount of success over the years.
*
Myositis companies working in the treatment market are JN Biosciences, ImmunoForge, Paean Biotechnology Inc., Merck KGaA, and others, are developing therapies for the Myositis treatment
*
Emerging Myositis therapies in the different phases of clinical trials are- HuABC2, PF1801, PN-101, M5049, and others are expected to have a significant impact on the Myositis market in the coming years.
*
In April 2025, Calibr-Skaggs Institute for Innovative Medicines, the drug discovery arm of Scripps Research, announced that the FDA has approved its investigational new drug (IND) application to evaluate its switchable chimeric antigen receptor T-cell (sCAR-T) therapy, CLBR001 in combination with SWI019, in patients with autoimmune diseases. Enrollment for the Phase I clinical trial (NCT06913608) is expected to begin shortly. The study will assess the safety and preliminary efficacy of the therapy in conditions such as myositis, systemic sclerosis, lupus, and rheumatoid arthritis, with the possibility of expanding into additional indications. The sCAR-T platform is designed to minimize side effects and reduce patient burden by avoiding the intensive lymphodepletion typically required with conventional CAR-T therapies, addressing a key concern for both patients and rheumatology specialists.
*
In March 2025, Abcuro, Inc., a clinical-stage biotech firm focused on treating autoimmune diseases and cancer by precisely targeting cytotoxic T cells, announced it will present safety, pharmacokinetic, and pharmacodynamic findings from its Phase 1 clinical trial of ulviprubart (ABC008) for inclusion body myositis (IBM) at the upcoming American Academy of Neurology (AAN) Annual Meeting.
*
In February 2025, Abcuro secured $200 million in Series C funding to advance the development of its first-in-class therapy for inclusion body myositis. The funding will support the completion of the registrational Phase 2/3 MUSCLE trial evaluating ulviprubart, as well as the preparation for its Biologics License Application (BLA) submission and eventual commercial launch.
*
In November 2024, argenx has chosen to advance the development of efgartigimod SC (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA trial for adults with idiopathic inflammatory myopathies. This decision follows positive topline results from the Phase 2 segment, where the study met its primary endpoint by showing a statistically significant improvement in the mean total improvement score (TIS) at Week 24. Moreover, efgartigimod SC demonstrated favorable outcomes across all six core TIS measures compared to placebo.
Myositis Overview
Myositis is a rare autoimmune disease characterized by inflammation and weakness of the skeletal muscles, particularly those closest to the trunk of the body. It is classified as an idiopathic inflammatory myopathy, meaning that its exact cause is unknown. However, it is believed to involve an abnormal immune response in which the body's immune system mistakenly attacks its own muscles.
Explore the latest Myositis pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Myositis Clinical Trials [https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Myositis Drugs Under Different Phases of Clinical Development Include:
*
HuABC2: JN Biosciences
*
PF1801: ImmunoForge
*
PN-101: Paean Biotechnology Inc.
*
M5049: Merck KGaA
Myositis Route of Administration
Myositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Inhalation
*
Inhalation/Intravenous/Oral
*
Intranasal
*
Intravenous
*
Intravenous/ Subcutaneous
*
NA
*
Oral
*
Oral/intranasal/subcutaneous
*
Parenteral
*
Subcutaneous
Myositis Molecule Type
Myositis Products have been categorized under various Molecule types, such as
*
Antibody
*
Antisense oligonucleotides
*
Immunotherapy
*
Monoclonal antibody
*
Peptides
*
Protein
*
Recombinant protein
*
Small molecule
*
Stem Cell
*
Vaccine
Myositis Pipeline Therapeutics Assessment
*
Myositis Assessment by Product Type
*
Myositis By Stage and Product Type
*
Myositis Assessment by Route of Administration
*
Myositis By Stage and Route of Administration
*
Myositis Assessment by Molecule Type
*
Myositis by Stage and Molecule Type
DelveInsight's Myositis Report covers around 20+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Myositis product details are provided in the report. Download the Myositis pipeline report to learn more about the emerging Myositis therapies [https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Myositis Therapeutics Market include:
Key companies developing therapies for Myositis are - F. Hoffmann-La Roche Ltd, Pfizer Inc, Zydus Group, Lupin, Bausch Health Companies Inc., Accord Healthcare, Genentech, Inc, Johnson & Johnson Services, Inc., Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Cipla Inc, Dr Reddy's Laboratories Ltd, Abbott, Bristol-Myers Squibb Company, GSK plc, Merz Pharma, Akorn, Incorporated, and others.
Myositis Pipeline Analysis:
The Myositis pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Myositis with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myositis Treatment.
*
Myositis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Myositis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myositis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Myositis drugs and therapies [https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Myositis Pipeline Market Drivers
*
Growing cases of chronic muscle inflammation, continuous advancement in technology, increased injuries of muscle are some of the important factors that are fueling the Myositis Market.
Myositis Pipeline Market Barriers
*
However, high cost of drugs, lack of approved therapies and other factors are creating obstacles in the Myositis Market growth.
Scope of Myositis Pipeline Drug Insight
*
Coverage: Global
*
Key Myositis Companies: JN Biosciences, ImmunoForge, Paean Biotechnology Inc., Merck KGaA, and others
*
Key Myositis Therapies: HuABC2, PF1801, PN-101, M5049, and others
*
Myositis Therapeutic Assessment: Myositis current marketed and Myositis emerging therapies
*
Myositis Market Dynamics: Myositis market drivers and Myositis market barriers
Request for Sample PDF Report for Myositis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Myositis Report Introduction
2. Myositis Executive Summary
3. Myositis Overview
4. Myositis- Analytical Perspective In-depth Commercial Assessment
5. Myositis Pipeline Therapeutics
6. Myositis Late Stage Products (Phase II/III)
7. Myositis Mid Stage Products (Phase II)
8. Myositis Early Stage Products (Phase I)
9. Myositis Preclinical Stage Products
10. Myositis Therapeutics Assessment
11. Myositis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Myositis Key Companies
14. Myositis Key Products
15. Myositis Unmet Needs
16 . Myositis Market Drivers and Barriers
17. Myositis Future Perspectives and Conclusion
18. Myositis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myositis-pipeline-2025-moa-and-roa-insights-clinical-trials-status-and-key-companies-involved-by-delveinsight-roche-pfizer-zydus-group-lupin-bausch-health-accord-healthcare-genentech]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myositis Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Roche, Pfizer, Zydus Group, Lupin, Bausch Health, Accord Healthcare, Genentech here
News-ID: 4383288 • Views: …
More Releases from ABNewswire
UK Taxpayers Seek Easy Tax Software as Digital Filing Becomes the New Normal
As digital tax filing becomes the default across the UK, taxpayers are increasingly searching for easy tax software that removes complexity from self assessment and online submissions. With more people managing freelance income, property earnings, and side work alongside PAYE employment, demand for simpler tools is rising. Industry data from Pie shows sustained growth in users choosing guided, app-based tax platforms over manual forms and spreadsheets.
LONDON, United Kingdom - February…
Top CPA in Dallas, Texas, Advises Clients to Prepare for Potential Shifts in Tax …
Dallas, TX - With comprehensive tax reform proposals under consideration, taxpayers and business owners face a landscape of potential changes that could reshape financial strategies for years to come. The proposals encompass wide-ranging modifications to individual deductions, capital gains treatment, estate tax exemptions, and business tax structures that require proactive planning and careful evaluation.
Jeff Badu, a well-known tax accountant in Dallas, Texas [https://www.abnewswire.com/pressreleases/tax-professional-in-dallas-tx-highlights-importance-of-early-retirement-planning-as-many-approach-retirement-unprepared_785667.html], advises clients to review their current tax…
Top Plant Maintenance Contractor in Bay Area CA Notes Wave of Office Relocations …
Bay Area, CA - As commercial lease expirations accelerate through 2026, businesses across Silicon Valley are rethinking their office strategies. Companies are downsizing while simultaneously upgrading to class A office spaces featuring biophilic design elements that integrate nature into the workplace. This shift reflects a strategic response to the hybrid work era, where premium environments can make the difference in bringing employees back to the office.
Jennifer Farmer, a plant maintenance…
Ardmore, PA Holistic Doctor Brings Enhanced Candida Cleansing Therapy in the Mai …
Ardmore, PA - Live Well Holistic Health Center announces enhanced treatment protocols following Dr. Martin Orimenko's completion of advanced training with renowned mentors Michael Lebowitz and Noah Lebowitz of Supreme Nutrition. The specialized training has equipped the practice with powerful new techniques for uncovering hidden causes of patient symptoms, particularly benefiting those seeking candida cleansing therapy in the Main Line, PA [https://www.abnewswire.com/pressreleases/natural-medicine-practitioner-in-ardmore-pa-marks-15-years-helping-main-line-patients-address-the-root-cause-of-illness_785743.html].
Dr. Martin Orimenko, a trusted natural medicine practitioner in…
More Releases for Myositis
Inflammatory Myositis Market Massive Growth opportunity Ahead
Introduction
Inflammatory myositis is a group of rare autoimmune disorders characterized by chronic inflammation of skeletal muscles, leading to progressive muscle weakness, fatigue, and functional disability. The spectrum includes polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), immune-mediated necrotizing myopathy (IMNM), and overlap syndromes. These disorders can also involve other organs, most notably the lungs (interstitial lung disease), skin, heart, and joints, complicating disease management.
Historically, corticosteroids and conventional immunosuppressants have formed…
Idiopathic Inflammatory Myositis Market Growth, Trends, Consumer Demand and Key …
Introduction
Idiopathic Inflammatory Myositis (IIM) is a rare group of autoimmune muscle diseases characterized by chronic inflammation of skeletal muscles, leading to progressive weakness, fatigue, and in severe cases, disability. The group includes dermatomyositis (DM), polymyositis (PM), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), and antisynthetase syndrome. IIM can also involve systemic complications such as interstitial lung disease (ILD), cardiac dysfunction, and malignancy association, making management highly complex.
Historically, treatment relied…
Inclusion Body Myositis Market: A Guide to Understanding the Process
The global Inclusion Body Myositis (IBM) market is projected to reach approximately USD 231.4 million by 2033, growing at a CAGR of 8.7% from 2024 to 2033.
Inclusion Body Myositis Market Overview
The Inclusion Body Myositis market is growing steadily due to increasing recognition and diagnosis of this rare neuromuscular disorder. Advances in therapeutic research focusing on inflammation and muscle degeneration are driving the development of targeted treatments. Rising patient awareness and…
Myositis Clinical Trials, Pipeline Insights, and Companies 2024
DelveInsight's, "Myositis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myositis pipeline landscape. It covers the Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances in Myositis Treatment…
Global Necrotizing Autoimmune Myositis Market - Opportunities & Forecasts, 2020- …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global necrotizing autoimmune myositis market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able…
Inclusion Body Myositis (IBM) - Pipeline Review And Industry Insight Report 2017
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and…
